Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE002 (USA) (Dr. Nolan)
· consented 2022-10-30
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-30 (study day 24); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-18 (study day 42); relationship: not assessed
severe
assessed
2026-08-18
Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-29 (study day 53); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-01-17 (study day 72); relationship: N
mild
assessed
2026-08-18
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-02-25 (study day 111); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.